Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacTRL Tri
- Development stage
- Preclinical
- Lead developer
- Symvivo
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravenous
01
Overview
bacTRL Tri is an investigational DNA-encoded gene therapy and vaccine candidate developed by Symvivo Corporation for the prevention or treatment of COVID-19. It utilizes the proprietary bacTRL™ platform, which employs a live, engineered probiotic bacterium, *Bifidobacterium longum*, as a vector to deliver plasmid DNA directly to host cells. Once administered orally or intravenously, the bacteria facilitate the delivery of genetic material encoding SARS-CoV-2 antigens into the patient's own cells. The 'Tri' designation suggests a trivalent approach, likely encoding three distinct viral antigens (such as the Spike, Nucleocapsid, and Membrane proteins) to elicit a broader immune response. This technology is designed to provide a stable, scalable, and potentially needle-free alternative to traditional mRNA or viral vector vaccines by enabling the patient's own body to produce the therapeutic proteins.
- Other names
- Symvivo COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on bacTRL Tri.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacTRL Tri.